Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis
Authors' conclusion
Although relapse often occurs, the long-term survival of MDA5-DM patients who survived the remission induction phase is generally favourable. The status of the anti-MDA5 antibody is associated with relapse. JAKi may improve the survival of refractory patients with severe MDA5-DM.
Study context
- Population
- Patients with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)
- Participants
- 154 patients
- Outcome
- Short-term and long-term outcomes, including survival, relapse and anti-MDA5 antibody titre
Main finding
As reported in the abstract
- Death during remission induction phase (respiratory failure most common cause)
- 40 (26.0%)
- 5-year cumulative survival among 114 surviving remission induction
- 96.8%
- 5-year relapse-free survival among 114 surviving remission induction
- 77.4%
- Complete drug-free remission
- 7.9%
- Normalization of anti-MDA5 antibody titres; only two relapsed after normalization
- 54
Observational data: associations, not effects.
Further findings
6-month survival in severe patients, after vs before emergence of Janus kinase inhibitors (JAKi) treatment
- 6-month survival significantly higher after emergence of JAKi treatment
- P = 0.03
Original publication
Short-term and long-term outcomes of patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. Rheumatology (Oxford). Published 12 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →